Background: The aims of this study were to investigate the effect of Helicobacter pylori eradication on gastroesophageal reflux, gastrointestinal symptoms and quality of life in patients with functional dyspepsia.
Methods: 20 H. pylori positive patients diagnosed as having functional dyspepsia according to Roma-II criteria completed the study period. Esophageal motility testing and pH recordings were obtained from each patient before and at the end of the study period. Each patient's gastrointestinal symptoms were evaluated according to Glasgow dyspepsia score. 36-Item short-form health survey (SF-36) and EDQ5 health survey were obtained form each patient.
Results: H. pylori eradication was accomplished in 13 patients (65%). Glasgow dyspepsia symptom score improved in H. pylori eradicated patients (10.3 vs 7.5, p<0.05) compared to baseline. Fasting lower esophageal sphincter pressures increased (21.6 vs 25.4 mmHg, p<0.05) after H. pylori eradication Neither the amplitude of peristaltic contractions in the esophageal body (59.4 vs 57.7 mmHg, p=ns) nor the velocity of peristaltic contractions changed before and after eradication. The percent time of esophageal pH<4 (0.7 vs 2.6, p<0.001), reflux events longer than 5 min (0 vs 0.7, p<0.005) and total reflux number (10.3 vs 19.3, p<0.005) significantly increased after eradication therapy. In the SF-36 health-related quality of life survey, general health score was 3.5 vs. 3.4, physical activity 25.2 vs. 26.4, physical role 5.9 vs. 6.3, emotional pain 4.6 vs. 4.5, social activity 2.0 vs. 1.9, physical pain 3.4 vs. 3.0, vitality 32.3 vs. 34.6, and mental health 11.9 vs. 11.5, before and at the end of treatment (p=ns), respectively.
Conclusions: H. pylori eradication did not influence quality of life in patients with functional dyspepsia. Majority of the patients experienced a significant change in esophageal acid exposure after H. pylori eradication. H. pylori eradication significantly decreases gastrointestinal symptoms, however has no effect on quality of life in patients with functional dyspepsia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2008.11.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Rifaximin Monotherapy and Rifaximin Combined with Probiotics in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial.
Nutrients
February 2025
Division of Gastroenterology, Department of Internal Medicine, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University of Korea, Seoul 07441, Republic of Korea.
: Rifaximin is a nonabsorbable antibiotic used to treat irritable bowel syndrome (IBS). Recent studies on eradication treatment have reported synergistic effects and low adverse effects when antibiotics are used in combination with probiotics; yet, such studies have not been conducted in IBS. Probiotics can enhance gut microbiota modulation, inhibition of pathogen adhesion to the gut epithelia, improvement in gut barrier function, anti-inflammatory effects, and improvement of gut immunity.
View Article and Find Full Text PDFAnalysis of garlic intake on atrophic gastritis risk in different infectious states of Helicobacter pylori in a case-control study.
Sci Rep
March 2025
Cancer Epidemiology Laboratory of Gansu Cancer Hospital, Lanzhou, 730000, Gansu Province, China.
In this case-control study, the main risk factors for atrophic gastritis (AG) were comprehensively analyzed in a real-world environment to identify potential risk factors associated with garlic intake and its effects on AG. Design Upper gastrointestinal endoscopy and pathological examination were performed as part of a gastric cancer screening and health check-up program. The detailed characteristics of both the case group and healthy control group were recorded and analyzed.
View Article and Find Full Text PDFACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions.
Am J Gastroenterol
March 2025
Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Gastric premalignant conditions (GPMC) are common and include atrophic gastritis, gastric intestinal metaplasia, dysplasia, and certain gastric epithelial polyps. GPMC have an increased risk of progression to gastric adenocarcinoma. Gastric cancer (GC) in the United States represents an important cancer disparity because incidence rates are 2- to 13-fold greater in non-White individuals, particularly early-generation immigrants from regions of high GC incidence.
View Article and Find Full Text PDFEndoscopic submucosal dissection (ESD), the standard treatment for early gastric cancer, typically results in homogeneous flat scars. However, in some cases, polypoid nodule scars (PNS) may develop, complicating the cancer recurrence assessment. This case report describes a 60-year-old man with a history of infection who underwent two ESD procedures: first for early antral gastric cancer and then for gastric body adenoma.
View Article and Find Full Text PDFNomogram prediction for gastric cancer development.
Clin Transl Gastroenterol
March 2025
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine.
Background: Helicobacter pylori (Hp) and gastric atrophy represent significant risk factors for gastric cancer. Nevertheless, to date no nomogram has been developed to predict gastric cancer based on the specific combination of risk factors, present in individual cases.
Methods: A retrospective-cohort study was conducted using health-screening data collected between 2003 and 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!